{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T12:50:22Z","timestamp":1784551822063,"version":"3.55.0"},"reference-count":77,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T00:00:00Z","timestamp":1685404800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2022MH058"],"award-info":[{"award-number":["ZR2022MH058"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2022QH168"],"award-info":[{"award-number":["ZR2022QH168"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.intimp.2023.110403","type":"journal-article","created":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T08:56:23Z","timestamp":1686128183000},"page":"110403","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["B7-H7: A potential target for cancer immunotherapy"],"prefix":"10.1016","volume":"121","author":[{"given":"Quanping","family":"Su","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyi","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingfang","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7752-8335","authenticated-orcid":false,"given":"Lijuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.intimp.2023.110403_b0005","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/s41423-020-0488-6","article-title":"The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications","volume":"17","author":"Zhang","year":"2020","journal-title":"Cell. Mol. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2023.110403_b0010","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41573-018-0006-z","article-title":"Delivery technologies for cancer immunotherapy","volume":"18","author":"Riley","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"issue":"7378","key":"10.1016\/j.intimp.2023.110403_b0015","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/nature10673","article-title":"Cancer immunotherapy comes of age","volume":"480","author":"Mellman","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2023.110403_b0020","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3389\/fonc.2014.00107","article-title":"Targeting T cell immunometabolism for cancer immunotherapy; understanding the impact of the tumor microenvironment","volume":"4","author":"Mockler","year":"2014","journal-title":"Front. Oncol."},{"issue":"6","key":"10.1016\/j.intimp.2023.110403_b0025","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.immuni.2022.04.016","article-title":"Dendritic cells can prime anti-tumor CD8(+) T cell responses through major histocompatibility complex cross-dressing","volume":"55","author":"MacNabb","year":"2022","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.intimp.2023.110403_b0030","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41571-018-0142-8","article-title":"Cancer immunoediting and resistance to T cell-based immunotherapy","volume":"16","author":"O'Donnell","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.intimp.2023.110403_b0035","doi-asserted-by":"crossref","first-page":"265","DOI":"10.4110\/in.2014.14.6.265","article-title":"The CD28-B7 Family in Anti-Tumor Immunity: Emerging Concepts in Cancer Immunotherapy","volume":"14","author":"Leung","year":"2014","journal-title":"Immune network"},{"key":"10.1016\/j.intimp.2023.110403_b0040","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1146\/annurev.iy.07.040189.002305","article-title":"Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy","volume":"7","author":"Mueller","year":"1989","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.intimp.2023.110403_b0045","doi-asserted-by":"crossref","first-page":"681","DOI":"10.3389\/fimmu.2020.00681","article-title":"Potential Therapeutic Targets of B7 Family in Colorectal Cancer","volume":"11","author":"Wang","year":"2020","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2023.110403_b0050","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/imr.12521","article-title":"The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7\u2013H3","volume":"276","author":"Janakiram","year":"2017","journal-title":"Immunol. Rev."},{"issue":"10","key":"10.1016\/j.intimp.2023.110403_b0055","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1158\/1078-0432.CCR-14-1495","article-title":"Expression, Clinical Significance, and Receptor Identification of the Newest B7 Family Member HHLA2 Protein","volume":"21","author":"Janakiram","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"24","key":"10.1016\/j.intimp.2023.110403_b0060","doi-asserted-by":"crossref","first-page":"9879","DOI":"10.1073\/pnas.1303524110","article-title":"HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T-cell function","volume":"110","author":"Zhao","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.intimp.2023.110403_b0065","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1038\/ncomms3043","article-title":"B7\u2013H5 costimulates human T cells via CD28H","volume":"4","author":"Zhu","year":"2013","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.intimp.2023.110403_b0070","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1006\/geno.1999.5877","article-title":"Endogenous retroviruses provide the primary polyadenylation signal for two new human genes (HHLA2 and HHLA3)","volume":"59","author":"Mager","year":"1999","journal-title":"Genomics"},{"issue":"7","key":"10.1016\/j.intimp.2023.110403_b0075","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1158\/1535-7163.MCT-16-0761","article-title":"New B7 Family Checkpoints in Human Cancers","volume":"16","author":"Ni","year":"2017","journal-title":"Mol. Cancer Ther."},{"issue":"8","key":"10.1016\/j.intimp.2023.110403_b0080","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s00251-012-0616-2","article-title":"Evolution of the B7 family: co-evolution of B7H6 and NKp30, identification of a new B7 family member, B7H7, and of B7's historical relationship with the MHC","volume":"64","author":"Flajnik","year":"2012","journal-title":"Immunogenetics"},{"issue":"10","key":"10.1016\/j.intimp.2023.110403_b0085","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1158\/1078-0432.CCR-14-2658","article-title":"A New B7:CD28 Family Checkpoint Target for Cancer Immunotherapy: HHLA2","volume":"21","author":"Xiao","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2023.110403_b0090","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.3389\/fimmu.2019.01573","article-title":"Prognostic Significance of Potential Immune Checkpoint Member HHLA2 in Human Tumors: A Comprehensive Analysis","volume":"10","author":"Wang","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2023.110403_b0095","doi-asserted-by":"crossref","first-page":"5421985","DOI":"10.1155\/2019\/5421985","article-title":"The Expression Patterns and Associated Clinical Parameters of Human Endogenous Retrovirus-H Long Terminal Repeat-Associating Protein 2 and Transmembrane and Immunoglobulin Domain Containing 2 in Oral Squamous Cell Carcinoma","volume":"2019","author":"Xiao","year":"2019","journal-title":"Dis. Markers"},{"issue":"9","key":"10.1016\/j.intimp.2023.110403_b0100","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1091\/mbc.e11-11-0934","article-title":"Identification of IGPR-1 as a novel adhesion molecule involved in angiogenesis","volume":"23","author":"Rahimi","year":"2012","journal-title":"Mol. Biol. Cell"},{"issue":"8","key":"10.1016\/j.intimp.2023.110403_b0105","doi-asserted-by":"crossref","first-page":"e1026534","DOI":"10.1080\/2162402X.2015.1026534","article-title":"HHLA2 and TMIGD2: new immunotherapeutic targets of the B7 and CD28 families","volume":"4","author":"Janakiram","year":"2015","journal-title":"Oncoimmunology"},{"issue":"2","key":"10.1016\/j.intimp.2023.110403_b0110","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1158\/2326-6066.CIR-20-0996","article-title":"Mystery Checkpoint Revealed: KIR3DL3 Finally Found a Ligand in HHLA2","volume":"9","author":"Campbell","year":"2021","journal-title":"Cancer Immunol. Res."},{"issue":"2","key":"10.1016\/j.intimp.2023.110403_b0115","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1158\/2326-6066.CIR-20-0315","article-title":"KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1","volume":"9","author":"Bhatt","year":"2021","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.intimp.2023.110403_b0120","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.3389\/fimmu.2019.01179","article-title":"Killer Ig-Like Receptors (KIRs): Their Role in NK Cell Modulation and Developments Leading to Their Clinical Exploitation","volume":"10","author":"Pende","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2023.110403_b0125","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3389\/fimmu.2019.00024","article-title":"Conservation, Extensive Heterozygosity, and Convergence of Signaling Potential All Indicate a Critical Role for KIR3DL3 in Higher Primates","volume":"10","author":"Leaton","year":"2019","journal-title":"Front. Immunol."},{"issue":"61","key":"10.1016\/j.intimp.2023.110403_b0130","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abf9792","article-title":"KIR3DL3-HHLA2 is a human immunosuppressive pathway and a therapeutic target","volume":"6","author":"Wei","year":"2021","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.intimp.2023.110403_b0135","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.682627","article-title":"B7\u2013H7 Is Inducible on T Cells to Regulate Their Immune Response and Serves as a Marker for Exhaustion","volume":"12","author":"Luu","year":"2021","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2023.110403_b0140","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1038\/s41423-020-0361-7","article-title":"B7\u2013H7 (HHLA2) inhibits T-cell activation and proliferation in the presence of TCR and CD28 signaling","volume":"18","author":"Rieder","year":"2021","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.intimp.2023.110403_b0145","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s12935-019-0813-2","article-title":"Overexpression of HHLA2 in human clear cell renal cell carcinoma is significantly associated with poor survival of the patients","volume":"19","author":"Chen","year":"2019","journal-title":"Cancer Cell Int."},{"issue":"8","key":"10.1016\/j.intimp.2023.110403_b0150","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1158\/1078-0432.CCR-17-2924","article-title":"Wide Expression and Significance of Alternative Immune Checkpoint Molecules, B7x and HHLA2, in PD-L1-Negative Human Lung Cancers","volume":"24","author":"Cheng","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.intimp.2023.110403_b0155","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1158\/1078-0432.CCR-15-3071","article-title":"HHLA2, a New Immune Checkpoint Member of the B7 Family, Is Widely Expressed in Human Lung Cancer and Associated with EGFR Mutational Status","volume":"23","author":"Cheng","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.intimp.2023.110403_b0160","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.31557\/APJCP.2021.22.6.1883","article-title":"Human Endogenous Retrovirus-H Long Terminal Repeat- Associating Protein 2 (HHLA2) is a Novel Immune Checkpoint Protein in Lung Cancer which Predicts Survival","volume":"22","author":"Farrag","year":"2021","journal-title":"Asian Pac. J. Cancer Prev."},{"issue":"10","key":"10.1016\/j.intimp.2023.110403_b0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2020.153134","article-title":"B7\u2013H4 and HHLA2, members of B7 family, are aberrantly expressed in EGFR mutated lung adenocarcinoma","volume":"216","author":"Chen","year":"2020","journal-title":"Pathol. Res. Pract."},{"issue":"6","key":"10.1016\/j.intimp.2023.110403_b0170","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2217\/imt-2021-0093","article-title":"Different clinical significance of novel B7 family checkpoints VISTA and HHLA2 in human lung adenocarcinoma","volume":"14","author":"Long","year":"2022","journal-title":"Immunotherapy"},{"issue":"5","key":"10.1016\/j.intimp.2023.110403_b0175","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1038\/s41388-021-02124-6","article-title":"B7\u2013H4 is increased in lung adenocarcinoma harboring EGFR-activating mutations and contributes to immunosuppression","volume":"41","author":"Lu","year":"2022","journal-title":"Oncogene"},{"issue":"15","key":"10.1016\/j.intimp.2023.110403_b0180","doi-asserted-by":"crossref","first-page":"5256","DOI":"10.1002\/cam4.4081","article-title":"HHLA2 deficiency inhibits non-small cell lung cancer progression and THP-1 macrophage M2 polarization","volume":"10","author":"Sun","year":"2021","journal-title":"Cancer Med."},{"issue":"4","key":"10.1016\/j.intimp.2023.110403_b0185","doi-asserted-by":"crossref","first-page":"568","DOI":"10.7150\/ijbs.39769","article-title":"Comprehensive understanding of B7 family in gastric cancer: expression profile, association with clinicopathological parameters and downstream targets","volume":"16","author":"Li","year":"2020","journal-title":"Int. J. Biol. Sci."},{"issue":"1","key":"10.1016\/j.intimp.2023.110403_b0190","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1007\/s13577-019-00280-2","article-title":"HHLA2 overexpression is a novel biomarker of malignant status and poor prognosis in gastric cancer","volume":"33","author":"Wei","year":"2020","journal-title":"Hum. Cell"},{"issue":"22","key":"10.1016\/j.intimp.2023.110403_b0195","article-title":"The Correlation of Ten Immune Checkpoint Gene Expressions and Their Association with Gastric Cancer Development","volume":"23","author":"Mansorunov","year":"2022","journal-title":"Int. J. Mol. Scie."},{"issue":"2","key":"10.1016\/j.intimp.2023.110403_b0200","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1530\/ERC-20-0337","article-title":"B7 immune-checkpoints as targets for the treatment of neuroendocrine tumors","volume":"28","author":"Yuan","year":"2021","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.intimp.2023.110403_b0205","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.2147\/OTT.S160493","article-title":"Overexpression of HHLA2, a member of the B7 family, is associated with worse survival in human colorectal carcinoma","volume":"11","author":"Zhu","year":"2018","journal-title":"OncoTargets and therapy"},{"issue":"6","key":"10.1016\/j.intimp.2023.110403_b0210","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24065876","article-title":"Overexpression and Role of HHLA2, a Novel Immune Checkpoint, in Colorectal Cancer","volume":"24","author":"Kula","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2023.110403_b0215","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.canlet.2018.11.007","article-title":"HHLA2 is a novel immune checkpoint protein in pancreatic ductal adenocarcinoma and predicts post-surgical survival","volume":"442","author":"Yan","year":"2019","journal-title":"Cancer Lett."},{"key":"10.1016\/j.intimp.2023.110403_b0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2022.153911","article-title":"Prognostic values of B7\u2013H3, B7\u2013H4, and HHLA2 expression in human pancreatic cancer tissues based on mIHC and spatial distribution analysis","volume":"234","author":"Zhu","year":"2022","journal-title":"Pathol. Res. Pract."},{"issue":"8","key":"10.1016\/j.intimp.2023.110403_b0225","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1038\/s41416-020-0755-4","article-title":"HHLA2 is expressed in pancreatic and ampullary cancers and increased expression is associated with better post-surgical prognosis","volume":"122","author":"Boor","year":"2020","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2023.110403_b0230","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s40425-019-0554-8","article-title":"HHLA2 in intrahepatic cholangiocarcinoma: an immune checkpoint with prognostic significance and wider expression compared with PD-L1","volume":"7","author":"Jing","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.intimp.2023.110403_b0235","doi-asserted-by":"crossref","first-page":"e930215","DOI":"10.12659\/MSM.930215","article-title":"H Long Terminal Repeat-Associating 2 (HHLA2) is a Biomarker of Advanced Stage Hepatocellular Carcinoma and Promotes Tumor Cell Development In Vitro","volume":"27","author":"Luo","year":"2021","journal-title":"Med. Sci. Monitor: Int. Med. J. Exp. Clin. Res."},{"key":"10.1016\/j.intimp.2023.110403_b0240","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.831101","article-title":"Comprehensive Analysis of HHLA2 as a Prognostic Biomarker and Its Association With Immune Infiltrates in Hepatocellular Carcinoma","volume":"13","author":"Ding","year":"2022","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2023.110403_b0245","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1007\/s10753-021-01547-3","article-title":"Interferon Gamma-Induced Interferon Regulatory Factor 1 Activates Transcription of HHLA2 and Induces Immune Escape of Hepatocellular Carcinoma Cells","volume":"45","author":"Wang","year":"2022","journal-title":"Inflammation"},{"key":"10.1016\/j.intimp.2023.110403_b0250","first-page":"329","article-title":"HHLA2 Expression is Associated with Poor Survival in Patients with Hepatocellular Carcinoma","volume":"15","author":"Xu","year":"2021","journal-title":"Biol.: Targets Therapy"},{"issue":"13","key":"10.1016\/j.intimp.2023.110403_b0255","doi-asserted-by":"crossref","first-page":"4039","DOI":"10.7150\/jca.53124","article-title":"LRP1B mutation: a novel independent prognostic factor and a predictive tumor mutation burden in hepatocellular carcinoma","volume":"12","author":"Liu","year":"2021","journal-title":"J. Cancer"},{"key":"10.1016\/j.intimp.2023.110403_b0260","doi-asserted-by":"crossref","first-page":"4217","DOI":"10.2147\/JIR.S324336","article-title":"Clinical Significance of the HHLA2 Protein in Hepatocellular Carcinoma and the Tumor Microenvironment","volume":"14","author":"Luo","year":"2021","journal-title":"J. Inflamm. Res."},{"issue":"4","key":"10.1016\/j.intimp.2023.110403_b0265","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1007\/s10753-022-01644-x","article-title":"HHLA2 Activates the JAK\/STAT Signaling Pathway by Binding to TMIGD2 in Hepatocellular Carcinoma Cells","volume":"45","author":"Guo","year":"2022","journal-title":"Inflammation"},{"issue":"1","key":"10.1016\/j.intimp.2023.110403_b0270","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1093\/ajcp\/aqab221","article-title":"HHLA2 Immune Checkpoint Is a Novel Prognostic Predictor in Hepatocellular Carcinoma","volume":"158","author":"Liao","year":"2022","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.intimp.2023.110403_b0275","doi-asserted-by":"crossref","first-page":"280","DOI":"10.3389\/fcell.2020.00280","article-title":"Over-Expression and Prognostic Significance of HHLA2, a New Immune Checkpoint Molecule, in Human Clear Cell Renal Cell Carcinoma","volume":"8","author":"Zhang","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"issue":"1","key":"10.1016\/j.intimp.2023.110403_b0280","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1136\/jmedgenet-2018-105454","article-title":"Upregulated immune checkpoint HHLA2 in clear cell renal cell carcinoma: a novel prognostic biomarker and potential therapeutic target","volume":"56","author":"Chen","year":"2019","journal-title":"J. Med. Genet."},{"issue":"9","key":"10.1016\/j.intimp.2023.110403_b0285","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14092111","article-title":"A Novel Machine Learning 13-Gene Signature: Improving Risk Analysis and Survival Prediction for Clear Cell Renal Cell Carcinoma Patients","volume":"14","author":"Terrematte","year":"2022","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.intimp.2023.110403_b0290","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000157","article-title":"HHLA2 and PD-L1 co-expression predicts poor prognosis in patients with clear cell renal cell carcinoma","volume":"8","author":"Zhou","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2023.110403_b0295","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1186\/s12967-022-03496-3","article-title":"The methyltransferase METTL3 promotes tumorigenesis via mediating HHLA2 mRNA m6A modification in human renal cell carcinoma","volume":"20","author":"Zhu","year":"2022","journal-title":"J. Transl. Med."},{"issue":"7","key":"10.1016\/j.intimp.2023.110403_b0300","doi-asserted-by":"crossref","first-page":"3610","DOI":"10.1111\/jcmm.16458","article-title":"Ferroptosis-related gene CHAC1 is a valid indicator for the poor prognosis of kidney renal clear cell carcinoma","volume":"25","author":"Li","year":"2021","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.intimp.2023.110403_b0305","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1186\/s12935-020-01331-7","article-title":"Identification of methylation-driven genes related to the prognosis of papillary renal cell carcinoma: a study based on The Cancer Genome Atlas","volume":"20","author":"Liu","year":"2020","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.intimp.2023.110403_b0310","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2022.912190","article-title":"A Prognostic Signature for Clear Cell Renal Cell Carcinoma Based on Ferroptosis-Related lncRNAs and Immune Checkpoints","volume":"13","author":"Dong","year":"2022","journal-title":"Front. Genet."},{"issue":"10","key":"10.1016\/j.intimp.2023.110403_b0315","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1089\/dna.2020.5601","article-title":"Identification and Comprehensive Validation of a DNA Methylation-Driven Gene-Based Prognostic Model for Clear Cell Renal Cell Carcinoma","volume":"39","author":"Zhang","year":"2020","journal-title":"DNA Cell Biol."},{"key":"10.1016\/j.intimp.2023.110403_b0320","doi-asserted-by":"crossref","first-page":"31154","DOI":"10.1038\/srep31154","article-title":"HHLA2, a member of the B7 family, is expressed in human osteosarcoma and is associated with metastases and worse survival","volume":"6","author":"Koirala","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.intimp.2023.110403_b0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.gene.2022.147086","article-title":"Silencing tumor-intrinsic HHLA2 potentiates the anti-tumoral effect of paclitaxel on MG63 cells: Another side of immune checkpoint","volume":"855","author":"Ahangar","year":"2023","journal-title":"Gene"},{"issue":"2","key":"10.1016\/j.intimp.2023.110403_b0330","first-page":"109","article-title":"Immune Landscape of the B7 and TNFR Families in Oral Squamous Cell Carcinoma","volume":"23","author":"Ren","year":"2020","journal-title":"Chin. J. Dental Res.: Off. J. Sci. Section Chin. Stomatological Assoc."},{"issue":"1","key":"10.1016\/j.intimp.2023.110403_b0335","doi-asserted-by":"crossref","first-page":"e23691","DOI":"10.1097\/MD.0000000000023691","article-title":"The clinical significance of HERV-H LTR -associating 2 expression in cervical adenocarcinoma","volume":"100","author":"Byun","year":"2021","journal-title":"Medicine"},{"issue":"1","key":"10.1016\/j.intimp.2023.110403_b0340","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1186\/s12935-021-01930-y","article-title":"HHLA2 predicts better survival and exhibits inhibited proliferation in epithelial ovarian cancer","volume":"21","author":"Xu","year":"2021","journal-title":"Cancer Cell Int."},{"issue":"6","key":"10.1016\/j.intimp.2023.110403_b0345","first-page":"2309","article-title":"HHLA2 is a novel prognostic predictor and potential therapeutic target in malignant glioma","volume":"42","author":"Qi","year":"2019","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.intimp.2023.110403_b0350","article-title":"Coexpression of HHLA2 and PD-L1 on Tumor Cells Independently Predicts the Survival of Spinal Chordoma Patients","volume":"12","author":"Xia","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2023.110403_b0355","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.2147\/IJGM.S338564","article-title":"Human Endogenous Retrovirus-H Long Terminal Repeat-Associating Protein 2 Possesses Prognostic Significance and Promotes Progression of Papillary Thyroid Cancer","volume":"15","author":"Niu","year":"2022","journal-title":"Int. J. General Med."},{"issue":"7","key":"10.1016\/j.intimp.2023.110403_b0360","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1093\/jjco\/hyac040","article-title":"High expression of HHLA2 predicts poor prognosis in medullary thyroid carcinoma","volume":"52","author":"Niu","year":"2022","journal-title":"Jpn. J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2023.110403_b0365","article-title":"HHLA2 predicts improved prognosis of anti-PD-1\/PD-L1 immunotherapy in patients with melanoma","volume":"13","author":"Huang","year":"2022","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2023.110403_b0370","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1159\/000495887","article-title":"Immune Checkpoint Human Endogenous Retrovirus-H Long Terminal Repeat-Associating Protein 2 is Upregulated and Independently Predicts Unfavorable Prognosis in Bladder Urothelial Carcinoma","volume":"141","author":"Lin","year":"2019","journal-title":"Nephron"},{"issue":"4","key":"10.1016\/j.intimp.2023.110403_b0375","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s11255-022-03458-0","article-title":"Increased co-expression of stromal HHLA2 and fibroblast activation protein in upper tract urothelial carcinoma","volume":"55","author":"Nishihara","year":"2023","journal-title":"Int. Urol. Nephrol."},{"issue":"2","key":"10.1016\/j.intimp.2023.110403_b0380","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.gendis.2020.08.003","article-title":"The combination of novel immune checkpoints HHLA2 and ICOSLG: A new system to predict survival and immune features in esophageal squamous cell carcinoma","volume":"9","author":"Zhang","year":"2022","journal-title":"Genes & diseases"},{"issue":"4","key":"10.1016\/j.intimp.2023.110403_b0385","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/jop.13289","article-title":"Expression of HHLA2, TMIGD2, and GITR in salivary gland adenoid cystic carcinoma and mucoepidermoid carcinoma","volume":"51","author":"Zhang","year":"2022","journal-title":"J. Oral Pathol. Med."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923007269?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923007269?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T18:02:31Z","timestamp":1761588151000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576923007269"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":77,"alternative-id":["S1567576923007269"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2023.110403","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"B7-H7: A potential target for cancer immunotherapy","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2023.110403","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"110403"}}